Erica Torchiaro

Erica Torchiaro

Auto-generated profile, based on publicly available information

Erica Torchiaro

Candiolo Cancer Institute, Candiolo, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Ymera PignochinoYmera Pignochino
Ymera Pignochino
CDCarmine Dell'Aglio
Carmine Dell'Aglio
MBMarco Basiricò
Marco Basiricò
FCFederica Capozzi
Federica Capozzi
MSMarco Soster
Marco Soster
GGGiovanni Grignani
Giovanni Grignani
Purpose: The multikinase inhibitor sorafenib displays antitumor activity in preclinical models of osteosarcoma. However, in sorafenib-treated patients with metastatic-relapsed osteosarcoma, disease stabilization and tumor shrinkage were short-lived and drug resistance occurred. We explored the sorafenib treatment escape mechanisms to overcome their drawbacks. Experimental Design: Immunoprecipitation, Western blotting, and immunohistochemistry were used to analyze the mTOR pathway [mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)]. Cell viability, colony growth, and cell migration were evaluated in different osteosarcoma cell lines (MNNG-HOS, HOS, KHOS/NP, MG63, U-2OS, SJSA-1, and SAOS-2) after scalar dose treatment with sorafenib (10–0.625 μmol/L), rapamycin-analog everolimus (100–6.25 nmol/L), and combinations of the two. Cell cycle, reactive oxygen species (ROS) production, and apoptosis were assessed by flow cytometry. Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice injected with MNNG-HOS cells were used to determine antitumor and antimetastatic effects. Angiogenesis and vascularization were evaluated in vitro by exploiting endothelial branching morphogenesis assays and in vivo in xenografted mice and chorioallantoic membranes. Results: After sorafenib treatment, mTORC1 signaling was reduced (downstream target P-S6), whereas mTORC2 was increased (phospho-mTOR Ser2481) in MNNG-HOS xenografts compared with vehicle-treated mice. Combining sorafenib with everolimus resulted in complete abrogation of both mTORC1 [through ROS-mediated AMP-activated kinase (AMPK) activation] and mTORC2 (through complex disassembly). The sorafenib/everolimus combination yielded: (i) enhanced antiproliferative and proapoptotic effects, (ii) impaired tumor growth, (iii) potentiated antiangiogenesis, and (iv) reduced migratory and metastatic potential. Conclusion: mTORC2 activation is an escape mechanism from sorafenib treatment. When sorafenib is combined with everolimus, its antitumor activity is increased by complete inhibition of the mTOR pathway in the preclinical setting. Clin Cancer Res; 19(8); 2117–31. ©2013 AACR.

18 January 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
GPGabriele Picco
Gabriele Picco
CPConsalvo Petti
Consalvo Petti
ACAlessia Centonze
Alessia Centonze
ETErica Torchiaro
Erica Torchiaro
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
EMEnzo Medico
Enzo Medico
In colorectal cancer (CRC), WNT pathway activation by genetic rearrangements of RSPO3 is emerging as a promising target. However, its low prevalence severely limits availability of preclinical models for in‐depth characterization. Using a pipeline designed to suppress stroma‐derived signal, we find that RSPO3 “outlier” expression in CRC samples highlights translocation and fusion transcript expression. Outlier search in 151 CRC cell lines identified VACO6 and SNU1411 cells as carriers of, respectively, a canonical PTPRK(e1)‐RSPO3(e2) fusion and a novel PTPRK(e13)‐RSPO3(e2) fusion. Both lines displayed marked in vitro and in vivo sensitivity to WNT blockade by the porcupine inhibitor LGK974, associated with transcriptional and morphological evidence of WNT pathway suppression. Long‐term treatment of VACO6 cells with LGK974 led to the emergence of a resistant population carrying two frameshift deletions of the WNT pathway inhibitor AXIN1, with consequent protein loss. Suppression of AXIN1 in parental VACO6 cells by RNA interference conferred marked resistance to LGK974. These results provide the first mechanism of secondary resistance to WNT pathway inhibition. ![][1] In colorectal cancer (CRC), translocations of the RSPO3 gene, leading to its expression as a fusion transcript, pinpoint a therapeutically actionable mechanism of Wnt pathway activation. EMBO Mol Med (2017) 9: 293–303 [1]: /embed/graphic-1.gif

28 August 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SPSimona Pavan
Simona Pavan
DMDaniele Musiani
Daniele Musiani
ETErica Torchiaro
Erica Torchiaro
GMGiorgia Migliardi
Giorgia Migliardi
MGMarta Gai
Marta Gai
MRMaria Flavia Di Renzo
Maria Flavia Di Renzo
The hepatocyte growth factor (HGF) also known as scatter factor activates cancer cell invasion and metastasis. We show that in ovarian cancer cells HGF induced the phosphorylation of the small heat shock protein of 27 kDa (HSP27) by activating the p38MAPK. HSP27 is increased in many cancers at advanced stage including ovarian cancer and associated with cancer resistance to therapy and poor patients' survival. The phosphorylation of HSP27 regulates both its chaperone activity and its control of cytoskeletal stability. We show that HSP27 was necessary for the remodeling of actin filaments induced by HGF and that motility in vitro depended on the p38MAPK‐MK2 axis. In vivo, HSP27 silencing impaired the ability of the highly metastatic, HGF‐secreting ovarian cancer cells to give rise to spontaneous metastases. This was due to defective motility across the vessel wall and reduced growth. Indeed, HSP27 silencing impaired the ability of circulating ovarian cancer cells to home to the lungs and to form experimental hematogenous metastases and the capability of cancer cells to grow as subcutaneous xenografts. Moreover, HSP27 suppression resulted in the sensitization of xenografts to low doses of the chemotherapeutic paclitaxel, likely because HSP27 protected microtubules from bundling caused by the drug. Altogether, these data show that the HSP27 is required for the proinvasive and prometastatic activity of HGF and suggest that HSP27 might be not only a marker of progression of ovarian cancer, but also a suitable target for therapy.

5 June 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
DMDaniele Musiani
Daniele Musiani
JKJohn David Konda
John David Konda
SPSimona Pavan
Simona Pavan
ETErica Torchiaro
Erica Torchiaro
FSFrancesco Sassi
Francesco Sassi
MRMaria Flavia Di Renzo
Maria Flavia Di Renzo
The tyrosine kinase encoded by the MET oncogene is activated by gene mutation or amplification in tumors, which in most instances maintain addiction, i.e. , dependency, to MET activation. This makes MET an attractive candidate for targeted therapies. Here we show that, in 3/3 MET‐addicted human gastric cancer cell lines, MET kinase inhibition resulted in a 3‐ to 4‐fold increased expression of the antiapoptotic small heat‐shock protein of 27 kDa (HSP27, HSPB1). HSP27 increase depended on the inhibition of the MEK/ERK pathway and on heat‐shock factor 1 (HSF1) and hypoxia‐inducible factor‐1α (HIF‐1α) regulation. Importantly, HSP27‐silenced MET‐addicted cells underwent 2‐ and 3‐fold more apoptosis following MET inhibition in vitro and in vivo , respectively. Likewise, in human cancer cells susceptible to epidermal growth factor receptor (EGFR) inhibition, EGFR inhibitors induced HSP27 expression and were strengthened by HSP27 suppression. In control cell lines that were not affected by drugs targeting MET or EGFR, these drugs did not induce HSP27 increase. Therefore, in cancer therapies targeting the MET pathway, the induction of HSP27 might limit the efficacy of anti‐MET agents. As HSP27 increase also impairs the effectiveness of EGFR inhibitors and is known to protect cells from chemotherapeutics, the induction of HSP27 by targeted agents might strongly affect the success of combination treatments.—Musiani, D., Konda, J. D., Pavan, S., Torchiaro, E., Sassi, F., Noghero, A., Erriquez, J., Perera, T., Olivero, M., Di Renzo, M. F. Heat‐shock protein 27 (HSP27, HSPB1) is up‐regulated by MET kinase inhibitors and confers resistance to MET‐targeted therapy. FASEB J. 28, 4055‐4067 (2014). www.fasebj.org

26 November 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
ETErica Torchiaro`
Erica Torchiaro`
ALAnnalisa Lorenzato
Annalisa Lorenzato
MOMartina Olivero
Martina Olivero
DVDonatella Valdembri
Donatella Valdembri
PGPaolo Armando Gagliardi
Paolo Armando Gagliardi
MRMaria Flavia Di Renzo
Maria Flavia Di Renzo
Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism

1 June 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
ALAnnalisa Lorenzato
Annalisa Lorenzato
ETErica Torchiaro
Erica Torchiaro
MOMartina Olivero
Martina Olivero
MRMaria Flavia Di Renzo
Maria Flavia Di Renzo